These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36888912)

  • 1. IP-LC-MSMS Enables Identification of Three Tau
    Bijttebier S; Rodrigues Martins D; Mertens L; Grauwen K; Bruinzeel W; Willems R; Bartolomé-Nebreda JM; Theunis C; Bretteville A; Ebneth A; Dillen L
    J Proteome Res; 2023 Apr; 22(4):1309-1321. PubMed ID: 36888912
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice.
    Hastings NB; Wang X; Song L; Butts BD; Grotz D; Hargreaves R; Fred Hess J; Hong KK; Huang CR; Hyde L; Laverty M; Lee J; Levitan D; Lu SX; Maguire M; Mahadomrongkul V; McEachern EJ; Ouyang X; Rosahl TW; Selnick H; Stanton M; Terracina G; Vocadlo DJ; Wang G; Duffy JL; Parker EM; Zhang L
    Mol Neurodegener; 2017 May; 12(1):39. PubMed ID: 28521765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The O-GlcNAc Modification of Recombinant Tau Protein and Characterization of the O-GlcNAc Pattern for Functional Study.
    El Hajjar L; Bridot C; Nguyen M; Cantrelle FX; Landrieu I; Smet-Nocca C
    Methods Mol Biol; 2024; 2754():237-269. PubMed ID: 38512671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of O-GlcNAc sites within peptides of the Tau protein and their impact on phosphorylation.
    Smet-Nocca C; Broncel M; Wieruszeski JM; Tokarski C; Hanoulle X; Leroy A; Landrieu I; Rolando C; Lippens G; Hackenberger CP
    Mol Biosyst; 2011 May; 7(5):1420-9. PubMed ID: 21327254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.
    Yu Y; Zhang L; Li X; Run X; Liang Z; Li Y; Liu Y; Lee MH; Grundke-Iqbal I; Iqbal K; Vocadlo DJ; Liu F; Gong CX
    PLoS One; 2012; 7(4):e35277. PubMed ID: 22536363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A genetic model to study
    St Amand MM; Bond MR; Riedy J; Comly M; Shiloach J; Hanover JA
    J Biol Chem; 2018 Aug; 293(35):13673-13681. PubMed ID: 29954943
    [No Abstract]   [Full Text] [Related]  

  • 7. O-GlcNAcylation and neurodegeneration.
    Wani WY; Chatham JC; Darley-Usmar V; McMahon LL; Zhang J
    Brain Res Bull; 2017 Jul; 133():80-87. PubMed ID: 27497832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MK-8719, a Novel and Selective
    Wang X; Li W; Marcus J; Pearson M; Song L; Smith K; Terracina G; Lee J; Hong KK; Lu SX; Hyde L; Chen SC; Kinsley D; Melchor JP; Rubins DJ; Meng X; Hostetler E; Sur C; Zhang L; Schachter JB; Hess JF; Selnick HG; Vocadlo DJ; McEachern EJ; Uslaner JM; Duffy JL; Smith SM
    J Pharmacol Exp Ther; 2020 Aug; 374(2):252-263. PubMed ID: 32493725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in O-Linked N-Acetylglucosamine (O-GlcNAc) Homeostasis Activate the p53 Pathway in Ovarian Cancer Cells.
    de Queiroz RM; Madan R; Chien J; Dias WB; Slawson C
    J Biol Chem; 2016 Sep; 291(36):18897-914. PubMed ID: 27402830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. O-Linked N-Acetylglucosamine (O-GlcNAc) Transferase and O-GlcNAcase Interact with Mi2β Protein at the Aγ-Globin Promoter.
    Zhang Z; Costa FC; Tan EP; Bushue N; DiTacchio L; Costello CE; McComb ME; Whelan SA; Peterson KR; Slawson C
    J Biol Chem; 2016 Jul; 291(30):15628-40. PubMed ID: 27231347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy.
    Graham DL; Gray AJ; Joyce JA; Yu D; O'Moore J; Carlson GA; Shearman MS; Dellovade TL; Hering H
    Neuropharmacology; 2014 Apr; 79():307-13. PubMed ID: 24326295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydroartemisinin promotes tau O-GlcNAcylation and improves cognitive function in hTau transgenic mice.
    Xia L; Li J; Pang Y; Xu M; Du Y; Chen M; Xu B; Qiu Y; Dong Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Dec; 135():111105. PubMed ID: 39053763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. O-GlcNAcase overexpression reverses coronary endothelial cell dysfunction in type 1 diabetic mice.
    Makino A; Dai A; Han Y; Youssef KD; Wang W; Donthamsetty R; Scott BT; Wang H; Dillmann WH
    Am J Physiol Cell Physiol; 2015 Nov; 309(9):C593-9. PubMed ID: 26269457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hexosamine biosynthetic pathway promotes the antiviral activity of SAMHD1 by enhancing O-GlcNAc transferase-mediated protein O-GlcNAcylation.
    Hu J; Gao Q; Yang Y; Xia J; Zhang W; Chen Y; Zhou Z; Chang L; Hu Y; Zhou H; Liang L; Li X; Long Q; Wang K; Huang A; Tang N
    Theranostics; 2021; 11(2):805-823. PubMed ID: 33391506
    [No Abstract]   [Full Text] [Related]  

  • 15. Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer's disease.
    Tramutola A; Sharma N; Barone E; Lanzillotta C; Castellani A; Iavarone F; Vincenzoni F; Castagnola M; Butterfield DA; Gaetani S; Cassano T; Perluigi M; Di Domenico F
    Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3309-3321. PubMed ID: 30031227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synapsin-1 and tau reciprocal O-GlcNAcylation and phosphorylation sites in mouse brain synaptosomes.
    Kang MJ; Kim C; Jeong H; Cho BK; Ryou AL; Hwang D; Mook-Jung I; Yi EC
    Exp Mol Med; 2013 Jun; 45(6):e29. PubMed ID: 23807304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of Intracellular Tau Aggregation Regulated by OGA/OGT Inhibitors.
    Lim S; Haque MM; Nam G; Ryoo N; Rhim H; Kim YK
    Int J Mol Sci; 2015 Aug; 16(9):20212-24. PubMed ID: 26343633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome.
    Zuliani I; Lanzillotta C; Tramutola A; Francioso A; Pagnotta S; Barone E; Perluigi M; Di Domenico F
    Neurotherapeutics; 2021 Jan; 18(1):340-363. PubMed ID: 33258073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developmental regulation of protein O-GlcNAcylation, O-GlcNAc transferase, and O-GlcNAcase in mammalian brain.
    Liu Y; Li X; Yu Y; Shi J; Liang Z; Run X; Li Y; Dai CL; Grundke-Iqbal I; Iqbal K; Liu F; Gong CX
    PLoS One; 2012; 7(8):e43724. PubMed ID: 22928023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer's disease and related tauopathies: analysis of the patent literature.
    Bartolomé-Nebreda JM; Trabanco AA; Velter AI; Buijnsters P
    Expert Opin Ther Pat; 2021 Dec; 31(12):1117-1154. PubMed ID: 34176417
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.